Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...

The FDA warned against unapproved sunscreen forms, while Australian tests exposed inaccurate SPF claims, causing consumer ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

Type 1 diabetes is a disease where the immune system destroys insulin-producing beta cells in pancreatic islets. About 2 million Americans have Type 1 diabetes. The islets of Langerhans are named for ...

Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...

Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...

However, one significant problem has proven surprisingly durable: misdiagnosis of Type 1 diabetes (T1D). Estimates suggest ...

The Managed Healthcare Executive 2025 State of the Industry survey is a timely snapshot of how payers, providers and pharmacy ...

A new influenza strain could fuel a severe flu season while a surge in measles cases threatens U.S. elimination status, ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...